ECSP23044970A - Compuestos y composiciones de moléculas pequeñas - Google Patents

Compuestos y composiciones de moléculas pequeñas

Info

Publication number
ECSP23044970A
ECSP23044970A ECSENADI202344970A ECDI202344970A ECSP23044970A EC SP23044970 A ECSP23044970 A EC SP23044970A EC SENADI202344970 A ECSENADI202344970 A EC SENADI202344970A EC DI202344970 A ECDI202344970 A EC DI202344970A EC SP23044970 A ECSP23044970 A EC SP23044970A
Authority
EC
Ecuador
Prior art keywords
compounds
compositions
small molecule
molecule compositions
methods
Prior art date
Application number
ECSENADI202344970A
Other languages
English (en)
Inventor
Mark Patrick Healy
Mairi Simie
David George Hubert Livermore
Adrian Hall
Santosh Kulkarni
Katherine Widdowson
Robert Joseph Allen Bell
James William Myatt
Original Assignee
Telo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telo Therapeutics Inc filed Critical Telo Therapeutics Inc
Publication of ECSP23044970A publication Critical patent/ECSP23044970A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se proporcionan compuestos y composiciones que inhiben la telomerasa y/o el gen de TERT con un promotor mutante. Además, se proporcionan compuestos o composiciones de moléculas pequeñas que tienen efectos beneficiosos en el tratamiento contra el cáncer. También se proporcionan métodos para elaborar los compuestos y las composiciones y métodos para usar los compuestos y las composiciones, tales como el uso de los compuestos y las composiciones para tratar el cáncer.
ECSENADI202344970A 2020-11-19 2023-06-15 Compuestos y composiciones de moléculas pequeñas ECSP23044970A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063115650P 2020-11-19 2020-11-19
US202163162049P 2021-03-17 2021-03-17
US202163278041P 2021-11-10 2021-11-10

Publications (1)

Publication Number Publication Date
ECSP23044970A true ECSP23044970A (es) 2023-08-31

Family

ID=81709818

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202344970A ECSP23044970A (es) 2020-11-19 2023-06-15 Compuestos y composiciones de moléculas pequeñas

Country Status (16)

Country Link
US (1) US20230416202A1 (es)
EP (1) EP4247374A4 (es)
JP (1) JP2023550473A (es)
KR (1) KR20230123954A (es)
AU (1) AU2021383768A1 (es)
BR (1) BR112023009665A2 (es)
CA (1) CA3202720A1 (es)
CL (1) CL2023001448A1 (es)
CO (1) CO2023007839A2 (es)
CR (1) CR20230258A (es)
EC (1) ECSP23044970A (es)
IL (1) IL303056A (es)
MX (1) MX2023005943A (es)
PE (1) PE20242103A1 (es)
TW (1) TW202235071A (es)
WO (1) WO2022109209A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202305359D0 (en) * 2023-04-12 2023-05-24 Univ Oxford Innovation Ltd Process
WO2026019666A1 (en) * 2024-07-15 2026-01-22 Telo Therapeutics, Inc. Piperidine compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312806D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
US5741800A (en) * 1993-06-22 1998-04-21 Knoll Aktiengesellachaft Azolyl-cyclic amine derivates with immunomodulatory activity
UA87986C2 (uk) * 2003-07-28 2009-09-10 Янссен Фармацевтика Н.В. Бензімідазольні, бензтіазольні та бензоксазольні похідні і їх застосування як lta4h модуляторів
GB0423356D0 (en) * 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
DE102009022892A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
CA2836791A1 (en) * 2011-05-20 2012-11-29 Benjamin Wolozin Identification of compounds that disperse tdp-43 inclusions

Also Published As

Publication number Publication date
CL2023001448A1 (es) 2023-10-30
TW202235071A (zh) 2022-09-16
EP4247374A1 (en) 2023-09-27
MX2023005943A (es) 2023-08-11
US20230416202A1 (en) 2023-12-28
BR112023009665A2 (pt) 2023-12-12
AU2021383768A9 (en) 2024-05-02
PE20242103A1 (es) 2024-10-28
JP2023550473A (ja) 2023-12-01
EP4247374A4 (en) 2024-10-09
CA3202720A1 (en) 2022-05-27
AU2021383768A1 (en) 2023-06-29
CR20230258A (es) 2023-09-12
CO2023007839A2 (es) 2023-10-09
KR20230123954A (ko) 2023-08-24
IL303056A (en) 2023-07-01
WO2022109209A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
ECSP24009853A (es) Compuestos tricíclicos como inhibidores de kras
ECSP24035717A (es) Compuestos de quinolina como inhibidores de kras
MX2024014142A (es) Novedosos inhibidores de molecula peque?a de factores de transcripcion tead
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
CL2019001353A1 (es) Compuestos con actividad antitumoral contra células cancerígenas que portan mutaciones en el exón 20 de egfr o her2.
MX2023007162A (es) Macrociclos y sus usos.
ECSP23044970A (es) Compuestos y composiciones de moléculas pequeñas
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CO2022014837A2 (es) Células t v delta1+ para el tratamiento de neoplasias mieloides
MX2022001004A (es) Inhibidores de enzimas.
CL2024003870A1 (es) Compuestos de degradación de wee1 y usos de los mismos
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
UY39779A (es) Compuestos macrocíclicos para tratar enfermedades
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
PE20220250A1 (es) Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
CL2025001070A1 (es) Compuestos, composiciones y métodos
MX2022010945A (es) Usos terapeuticos de compuestos macrociclicos.
MX2022003398A (es) Composicion micelar inmunoestimulante.
ECSP22093652A (es) Compuestos de imidazopiridazina y usos de los mismos
MX2021011610A (es) Combinaciones de iadademstat para terapia contra el cancer.
CL2022002527A1 (es) Células t v delta1 para el tratamiento de neoplasias mieloides
AR117459A1 (es) Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos